Implementing quality by design for biotech products: Are regulators on track?

Area of Science:

• Biotechnology
• Pharmaceutical Sciences
• Regulatory Science

Background:

• Quality by Design (QbD) is increasingly adopted in drug development, primarily for chemical drugs.
• The European Union recently authorized the first monoclonal antibody developed using extensive QbD principles.
• This marks a significant step for regulatory acceptance of complex biotechnological products developed with QbD.

Purpose of the Study:

• To share insights and lessons learned from regulatory discussions on implementing QbD for biotechnology-derived medicinal products.
• To highlight key issues encountered during the evaluation of extensive QbD approaches for these complex products.
• To provide guidance for future QbD applications in biotech and monoclonal antibody development.

Main Methods:

• Analysis of non-public discussions within the European Medicines Agency's Biologicals Working Party.
• Review of key issues discussed in the Committee for Medicinal Products for Human Use regarding QbD implementation.
• Commentary on the practical challenges and regulatory considerations for extensive QbD in biologics.

Main Results:

• Extensive QbD implementation for biotechnology products presents unique evaluation challenges.
• Regulatory bodies are actively engaging with QbD concepts for complex biologics.
• Successful authorization of a QbD-developed monoclonal antibody demonstrates feasibility.

Conclusions:

• Sharing regulatory insights is crucial for advancing QbD in biotechnology drug development.
• The lessons learned can guide future submissions and regulatory approvals for biotech products.
• This work supports the broader adoption of QbD for monoclonal antibodies and other complex biologics.